Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from treatment with hypomethylating agents (HMAs), but no predictive biomarkers for therapy response exist. Here, we investigated whether unbiased genome-wide assessment of pre-treatment DNA-methylation profiles in AML bone marrow blasts can help to identify patients who will achieve a remission after an azacytidine-containing induction regimen.

Results

A total of n = 155 patients with newly diagnosed AML treated in the AMLSG 12-09 trial were randomly assigned to a screening and a refinement and validation cohort. The cohorts were divided according to azacytidine-cont

SUBMITTER: Schmutz M 

PROVIDER: S-EPMC10601277 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature